Age-Related Changes in the Inflammatory Status of Human Mesenchymal Stem Cells: Implications for Cell Therapy

Human mesenchymal stem/stromal cell (hMSC)-based cell therapies are promising for treating a variety of diseases. The unique immunomodulatory properties of hMSCs have extended their therapeutic potential beyond tissue regeneration. However, extensive pre-clinical culture expansion inevitably drives cells toward replicative ?aging?and a consequent decline in quality. These ?in vitro-aged?hMSCs resemble biologically aged cells, which have been reported to show senescence signatures, diminished immunosuppressive capacity, and weakened regenerative potential as well as pro-inflammatory features. In this review, we have surveyed the literature to explore the intimate relationship between the inflammatory status of hMSCs and their in vitro aging process. We posit that a shift from an anti-inflammatory to a pro-inflammatory phenotype of culture-expanded hMSCs contributes to a deterioration in their therapeutic efficacy. Potential molecular and cellular mechanisms underpinning this phenomenon have been discussed. We have also highlighted studies that leverage these mechanisms to make culture-expanded hMSCs more amenable for clinical use.

Automated summary

Human mesenchymal stem/stromal cell-based cell therapies show promise in treating a variety of diseases, but extensive pre-clinical culture expansion can lead to cell replicative aging and decline in quality. The shift from an anti-inflammatory to a pro-inflammatory phenotype in culture-expanded cells may contribute to a deterioration in their therapeutic efficacy. Understanding the molecular and cellular mechanisms underlying this phenomenon is essential for improving the clinical utility of these cells.